Tesla (NASDAQ:TSLA) took investors by surprise last month when the electric-car company swung from a loss to a meaningful profit. On a non-GAAP basis, Tesla earned $2.90 per share, crushing a consensus analyst estimate for non-GAAP EPS of just $0.17. GAAP earnings and free cash flow for the period were impressive, too. The company’s sudden profitability comes as Model 3 deliveries are surging.
The recent stock market sell-off has created opportunities, but it’s also increased risks, especially if you invest in high-flying industries such as biotech that can pop or drop significantly on any day because of clinical trial news. To help you find the best biotech stocks to buy now, we asked three Fool contributors for their best ideas now. There’s no telling what’s in store next for these companies, but they think Global Blood Therapeutics (NASDAQ:GBT), Supernus Pharmaceuticals (NASDAQ:SUPN), and bluebird bio (NASDAQ:BLUE) are top stocks that biotech investors ought to be adding to portfolios this month.
October had more tricks than treats for investors. The markets started clawing their way back during the final two days of the month, but some stocks have still dug themselves into pretty big holes. Many will stay there, but let’s size up the ones that should not.
Imagine that in the next few decades, vehicles will slowly evolve from machines that we are entirely in control of to ones that become artificially intelligent chauffeurs, tirelessly carting us around town day and night.
Want a high-growth stock but don’t want to deal with the exceptional volatility and concerns about business longevity that come with owning small-cap stocks? Then say hello to mid-cap stocks, which can offer the perfect blend of growth, value, and more established business models.
First Snap (NYSE:SNAP) was a vanishing-message social media platform. Then management decided it was a camera company and set its eyes on drones. Now, apparently, it wants to become a video programming channel.
The world needs to invest an estimated $10 trillion in the decades ahead to replace its current carbon-based power systems. The market opportunity is even larger when factoring in energy-demand growth and the electrification of transportation. That positions renewable power companies like Pattern Energy Group (NASDAQ:PEGI) for a massive upside in the coming years.
A 3.5% dividend yield and a long track record of dividend increases have turned PepsiCo Inc.(NASDAQ:PEP) into a core holding for many income investors, but Pepsi isn’t the only big company that’s paying a market-beating dividend. In fact, other companies may offer investors a better blend of potential price appreciation and dividends than it does. To help you find those stocks, we asked three Motley Fool contributors to offer up companies they like more than Pepsi. Read on to find out why they think Pepsi lovers ought to consider TerraForm Power(NASDAQ:TERP), AstraZeneca. (NYSE:AZN), and Royal Dutch Shell (NYSE:RDS-A)(NYSE:RDS-B) instead.
Netflix‘s (NASDAQ:NFLX) third-quarter earnings report is scheduled to be released next week. As usual, one key metric investors will be watching is member growth. Netflix’s net member additions for a given quarter provide insight into how well the company is retaining and attracting members — obviously a key narrative for a company whose entire business model is based on a monthly subscription.
Another week, another five-year low for Rite Aid (NYSE:RAD) investors. Shares of the meandering drugstore operator plummeted another 10% last week, but the entire hit came during first two trading days of last week. Rite Aid has closed at exactly $1.15 for four consecutive trading days. It’s a coincidence, sure, but also a sign of potential stability.